Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial

Larry A Weinrauch, Brian Claggett, Jiankang Liu, Peter V Finn, Matthew R Weir, Daniel E Weiner, John A D'Elia, Larry A Weinrauch, Brian Claggett, Jiankang Liu, Peter V Finn, Matthew R Weir, Daniel E Weiner, John A D'Elia

Abstract

Background: Tobacco use remains an international health problem with between 10% and 40% of adults currently using tobacco. Given the rising number of patients either awaiting or having received a kidney transplant and the absence of smoking cessation as the criterion for transplantation in guidelines, we explored the association between smoking status and clinical outcomes in kidney transplant recipients.

Patients and methods: In this post hoc analysis of the Folic Acid for Vascular Outcome Reduction in Transplant trial, the associations between smoking status, defined as never having smoked, formerly or currently smoking, and both all-cause mortality and graft survival were assessed using Cox proportional hazards models. Fatal events were centrally adjudicated into prespecified categories: all-cause, cardiovascular and non-cardiovascular causes. Graft loss was defined as return to dialysis or retransplantation. Clinical Trials URL: http://www.clinicaltrials.gov/show/NCT00064753.

Results: Among 4110 transplant recipients, there were 451 current smokers and 1611 former smokers. The mortality rate per 100 patient-years was 4.0 (71 deaths) for smokers, 3.5 (226 deaths) for former smokers and 2.4 (116 deaths) for never smokers. Hazard ratio for mortality for current smokers was 1.70 (CI=1.26-2.29, p=0.001) and for former smokers was 1.21 (0.98-1.50, p=0.08) with 1.0 representing never smokers. As the number of cardiovascular deaths was similar in each group (all p>0.3), the differences between groups was driven by non-cardiovascular death rates. Current smokers (2.39; 1.62-3.61, p<0.001) and former smokers (1.50; 1.12-2.01, p=0.007) had increased hazard of non-cardiovascular death. Kidney allograft failure was more likely in current smokers than in either former or never smokers (3.5, 2.1 and 2.0 per 100 patient-years, p<0.001, adjusted hazard ratio 1.49 and 1.05, respectively).

Conclusion: Continued smoking was associated with >100% increased risk of non-cardiovascular death, 70% greater risk of all-cause mortality and a 50% greater risk of graft loss, a risk not seen in former smokers. These findings confirm previous non-adjudicated observations that smoking is associated with adverse clinical outcomes and suggest that more emphasis should be placed on smoking cessation prior to kidney transplantation.

Keywords: diabetes; graft loss; infection; infectious death; non-cardiovascular mortality; tobacco; transplant loss.

Conflict of interest statement

Disclosure All authors declare an absence of conflicts of interest relevant to this NIH funded study.

Figures

Figure 1
Figure 1
Patient survival outcomes based upon smoking history (all-cause mortality, CV mortality, non-CV mortality). Notes: (A) All transplant recipients. (B) Nonliving donor allograft recipients (cadaver). (C) Living donor allograft recipients (living). Abbreviations: CV, cardiovascular; CVD, cardiovascular disease.
Figure 1
Figure 1
Patient survival outcomes based upon smoking history (all-cause mortality, CV mortality, non-CV mortality). Notes: (A) All transplant recipients. (B) Nonliving donor allograft recipients (cadaver). (C) Living donor allograft recipients (living). Abbreviations: CV, cardiovascular; CVD, cardiovascular disease.
Figure 2
Figure 2
Composite of death or return to dialysis based upon smoking status.

References

    1. Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation. 1998;66(7):951–956.
    1. Orens JB, Estenne M, Arcasoy S, et al. Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25(7):745–755.
    1. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant. 2006;25(9):1024–1042.
    1. Martin P, DiMartini A, Feng S, Brown R, Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144–1165.
    1. Dudley C, Harden P. Renal association clinical practice guideline on the assessment of the potential kidney transplant recipient. Nephron Clin Pract. 2011;118(Suppl 1):c209–c224.
    1. Abramowicz D, Cochat P, Claas FH, et al. European renal best practice guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant. 2015;30(11):1790–1797.
    1. Schneider A, Jardine AG, Schneider MP, et al. Determinants of cardiovascular risk in haemodialysis patients: post hoc analyses of the AURORA study. Am J Nephrol. 2013;37(2):144–151.
    1. Leggat JE, Jr, Orzol SM, Hulbert-Shearon TE, et al. Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis. 1998;32(1):139–145.
    1. Bostom AG, Carpenter MA, Kusek JW, et al. FAVORIT Investigators Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Am Heart J. 2006;152(3):448e1–e7.
    1. Bostom AG, Carpenter MA, Hunsicker L, et al. FAVORIT Study Investigators Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Am J Kidney Dis. 2009;53(1):121–128.
    1. Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. Circulation. 2011;123(16):1763–1770.
    1. Maamoun HA, Soliman AR, Fathy A, Elkhatib M, Shaheen N. Diabetes mellitus as predictor of patient and graft survival after kidney transplantation. Transplant Proc. 2013;45(9):3245–3248.
    1. Hayer MK, Farrugia D, Begaj I, Ray D, Sharif A. Infection-related mortality is higher for kidney allograft recipients with pretransplant diabetes mellitus. Diabetologia. 2014;57(3):554–561.
    1. Weinrauch LA, D’Elia JA, Weir MR, et al. Infection and malignancy outweigh cardiovascular mortality in kidney transplant recipients: post Hoc analysis of the FAVORIT trial. Am J Med. 2018;131(2):165–172.
    1. Cosio FG, Falkenhain ME, Pesavento TE, et al. Patient survival after renal transplantation: II. The impact of smoking. Clin Transplant. 1999;13(4):336–341.
    1. Pungpapong S, Manzarbeitia C, Ortiz J, et al. Cigarette smoking is associated with an increased incidence of vascular complications after liver transplantation. Liver Transpl. 2002;8(7):582–587.
    1. Leithead JA, Ferguson JW, Hayes PC. Smoking-related morbidity and mortality following liver transplantation. Liver Transpl. 2008;14(8):1159–1164.
    1. Van der Heide F, Dijkstra G, Porte RJ, Kleibeuker JH, Haagsma EB. Smoking behavior in liver transplant recipients. Liver Transpl. 2009;15(6):648–655.
    1. Weinrauch LA, D’Elia JA, Monaco AP, et al. Preoperative evaluation for diabetic renal transplantation: the impact of clinical, laboratory, and echocardiographic evaluation on patient and allograft survival. Am J Med. 1992;93(1):19–28.
    1. West JC, Napoliello DA, Costello JM, et al. Preoperative dobutamine stress echocardiography versus cardiac arteriography for risk assessment prior to renal transplantation. Transpl Int. 2000;13(Suppl 1):S27–S30.
    1. Hurst FP, Altireri M, Patel PP, et al. Effect of smoking on transplant outcomes: analysis of the United States Renal Data System. Transplantation. 2011;92(10):1101–1107.
    1. Hecht EM, Arheart KL, Hennekens CH, Hlaing WM. Interrelation of Cadmium, smoking, and cardiovascular disease (from the National Health and Nutrition Examination Survey) Am J Cardio. 2016;118(2):204–209.
    1. Arend SM, Mallat MJ, Westendorp RJ, van der Woude FJ, van Es LA. Patient survival after renal transplantation; more than 25 years followup. Nephrol Dial Transplant. 1997;12(8):1672–1679.
    1. Cosio FG, Alimir A, Yim S, et al. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int. 1998;53(3):767–772.
    1. Doyle SE, Matas AJ, Gillingham K, Rosenberg ME. Predicting clinical outcome in the elderly renal transplant recipient. Kidney Int. 2000;57(5):2144–2150.
    1. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000;11(9):1735–1743.
    1. Woo YM, McLean D, Kavanagh D, et al. The influence of pre-operative electrocardiographic abnormalities and cardiovascular risk factors on patient and graft survival after renal transplantation. J Nephrol. 2002;15(4):380–386.
    1. de Mattos AM, Prather J, Olyaei AJ, et al. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int. 2006;70(4):757–764.
    1. Nogueira JM, Haririan A, Jacobs SC, Cooper M, Weir MR. Cigarette smoking, kidney function, and mortality after live donor kidney transplant. Am J Kidney Dis. 2010;55(5):907–915.
    1. Agarwal PK, Hellemons ME, Zelle DM, et al. Smoking is a risk factor for graft failure and mortality after renal transplantation. Am J Nephrol. 2011;34(1):26–31.
    1. Corbett C, Armstrong MJ, Neuberger J. Tobacco smoking and solid organ transplantation. Transplantation. 2012;94(10):979–987.
    1. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988;84(6):985–992.
    1. Israni AK, Snyder JJ, Skeans MA, et al. PORT Investigators Predicting coronary heart disease after kidney transplantation: patient outcomes in renal transplantation (PORT) study. Am J Transplant. 2010;10(2):338–353.
    1. Karavitis J, Kovacs EJ. Macrophage phagocytosis: effects of environmental pollutants, alcohol, cigarette smoke, and other external factors. J Leukoc Biol. 2011;90(6):1065–1078.
    1. Nankivell BJ, Kuypers DRJ. Organ transplantation 3: diagnosis and prevention of chronic kidney allograft loss. Lancet. 2011;378(9800):1428–1435.
    1. Duerinckx N, Burkhalter H, Engberg SJ, et al. B-SERIOUS consortium Correlates and outcomes of posttransplant smoking in solid organ transplant recipients: a systematic literature review and meta-analysis. Transplantation. 2016;100(11):2252–2263.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj